Clinical Report: Genetic Factors Linked to Depression in Latin American Communities

Overview

This systematic review identifies genetic factors associated with depression in Latin American populations, highlighting the underrepresentation of these communities in genetic research. Key findings include specific single-nucleotide polymorphisms (SNPs) linked to depression severity and treatment response.

Background

Depression is a major global health issue, particularly in low- and middle-income countries where stigma and limited resources hinder effective management. Understanding genetic predispositions in diverse populations is crucial for developing personalized treatment strategies. This review addresses the gap in research focused on Latin American populations, which may lead to improved diagnostic and therapeutic approaches.

Data Highlights

Key Findings

• Forty-five studies identified 306 genetic variants linked to depression in Latin American cohorts.
• Fourteen variants were replicated across at least two independent cohorts.
• Variants in SLC6A4 and COMT were the most consistently reported.
• The COMT Met allele was associated with increased symptom severity and poorer SSRI response.
• Genetic polymorphisms show significant variability across different Latin American populations.

Clinical Implications

Clinicians should consider the genetic diversity within Latin American populations when diagnosing and treating depression. Personalized medicine approaches, informed by genetic research, may enhance treatment efficacy and reduce the stigma associated with mental health disorders in these communities.

Conclusion

This review underscores the importance of including Latin American populations in genetic research to better understand depression and improve treatment outcomes. Continued efforts in this area are essential for advancing personalized mental health care.

Related Resources & Content

1. BMC Psychiatry, Springer, 2023 -- Exploring the Genetic Connections and Treatment Opportunities Between Major Depressive Disorder and Metabolic Syndrome
2. JAMA Network Open, 2023 -- Genotype-Guided Antidepressant Prescribing for Patients With Depression: A Randomized Clinical Trial
3. Drugs - Real World Outcomes, 2023 -- Investigation of the Link Between Antidepressant Use and Postpartum Hemorrhage: Insights from a Mendelian Randomization Analysis
4. Mental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders, WHO, 2023
5. Frontiers in Psychiatry — Large-scale meta- and cross-trait analyses uncover shared genetic risk factors for IBS and psychiatric disorders
6. Latin American Genomics Consortium (LAGC)
7. Mental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders
8. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial - PMC
9. Pharmacogenetic Implications for Antidepressant Therapy in Major Depression: A Systematic Review Covering 2019-2024 - PubMed
10. Multi-ancestry genome-wide association study of major depression aids locus discovery, fine mapping, gene prioritization and causal inference | Nature Genetics
11. Integrating Polygenic Scores and Phenotypic Data to Understand Psychiatric Outcomes | American Journal of Psychiatry
12. Genetic polymorphisms of CYP2C19 in ecuadorian population: An interethnic approach - ScienceDirect